ViewPoint
ViewPoint develops a nonsurgical route to cataract treatment.
Cypre and Molecular Devices sign co-marketing agreement to collaborate on delivering solutions for screening biologically relevant assays
Kolin Hribar, PhD, CEO and Founder of Cypre Inc. with their Symphony®/VersaGel® Cypre and Molecular Devices signed a co-marketing agreement to jointly market Cypre’s Symphony®/VersaGel® 3D cel [...]
Prellis Biologics and CELLINK Sign Partnership
Prellis Biologics and CELLINK Sign Partnership Prellis Biologics and CELLINK sign partnership to commercialize high-resolution holographic bioprinting technology for micro-printing.The partners [...]
Mammoth Biosciences raises $23M for its CRISPR-based disease detection engine
After completing their graduate work at Stanford, Trevor Martin and Ashley Tehranchi took 2 benches at MBC BioLabs to launch Mammoth Biosciences. Now, only seven months later, they and their colleagu [...]
LI-COR places flagship infrared imaging system in San Francisco and San Carlos
Expanding the capabilities of our FastTrack Core, LI-COR has placed their Odyssey CLx infrared imaging system at both MBC BioLabs Bay Area locations. The instrument’s broad, linear dynamic range accur [...]
Female Founders in Science
On June 26, Reshma Khilnani (Co-CEO, Droplet Health) hosted a standing-room-only panel discussion with female founders of biotechnology startups emerging from MBC BioLabs. The august panel included As [...]
GraphWear Technologies Raises a $4.2M Series A
Read Full Press Release GraphWear makes a graphene-based sensor technology that can provide biological information from sweat. Initially ideated to provide performance athletes with advanced informat [...]
ViewPoint Therapeutics Raises $35 Million in Series B Financing
Proceeds will advance lead product candidate through clinical proof-of-concept studies in cataracts and presbyopia Series B led by The Rise Fund, a global impact fund SAN FRANCISCO, Calif., March 5, [...]
Enable Biosciences, Stanford, and JDRF announce $700K Research Partnership
to Develop Improved Screening and Early Diagnosis Tests for Type 1 Diabetes Enable Biosciences, a UC Berkeley and Stanford-StartX diagnostics company at MBC BioLabs, and Stanford’s Division of Pediat [...]
Pionyr Immunotherapeutics Completes $62M Series B Financing
to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment Pionyr Immunotherapeutics, a company at QB3@953, is developing antibody therapeutics that increase the body's antitumor imm [...]